What is MedLumics?
Headquartered in Madrid, MedLumics specializes in the design and development of advanced medical instrumentation. The company's core innovation, the AblaView system, provides clinicians with real-time optical guidance during radio-frequency ablation procedures. By enabling the direct assessment of catheter positioning on the myocardium, as well as the continuity and transmurality of the ablation, MedLumics is effectively redefining precision in cardiac surgery. The company operates at the intersection of high-end medical engineering and life sciences, positioning itself as a critical player in the global effort to improve patient outcomes for complex heart rhythm disorders.
How much funding has MedLumics raised?
MedLumics has raised a total of $63.3M across 3 funding rounds:
Series A
$4.7M
Series B
$36.9M
Other Financing Round
$21.7M
Series A (2011): $4.7M with participation from Caixa Capital Risc and Ysios Capital Partners
Series B (2017): $36.9M led by Seroba Life Sciences, Caixa Capital Risc, Innogest Capital, Edmond de Rothschild Investment, and Ysios Capital Partners
Other Financing Round (2021): $21.7M supported by CDTI Innvierte Economía, Kurma Partners, VI Partners Swiss Innovation, and Asabys Partners Company
Key Investors in MedLumics
Caixa Capital Risc
A venture capital firm focused on early-stage investments in technology and biotechnology, managing specialized funds to support innovative startups.
Ysios Capital Partners
A leading life sciences venture capital firm that provides resources to biotech ventures focused on developing novel therapies for high unmet medical needs.
Seroba Life Sciences
A European life sciences venture capital firm dedicated to investing in biotech and medtech innovations by partnering with entrepreneurs to build businesses around extraordinary science.
What's next for MedLumics?
With the support of its latest strategic financing, MedLumics is well-positioned to accelerate its commercialization efforts and expand its clinical footprint. The company's focus will likely shift toward broader market adoption of the AblaView system and the potential development of next-generation diagnostic and therapeutic tools. By leveraging its established relationships with specialized life sciences investors, MedLumics is poised to navigate the regulatory and clinical hurdles necessary to solidify its market leadership. Future growth will be driven by the continued validation of its optical guidance technology, aiming to set a new standard of care in the electrophysiology market.
See full MedLumics company page
